Combining endocrine agents with chemotherapy: which patients and what sequence?

Area of Science:

• Medical Oncology
• Pharmacology
• Clinical Trials

Background:

• Combining hormone therapy and chemotherapy for metastatic breast cancer has been explored since the 1970s.
• Randomized trials often show increased response rates or time to progression with combined or sequential treatments.
• However, significant improvements in overall survival have not been consistently demonstrated.

Purpose of the Study:

• To evaluate the efficacy of concurrent versus sequential hormone therapy and chemotherapy in metastatic breast cancer.
• To determine if combined treatments offer superior response rates and duration compared to sequential administration.
• To highlight the need for further research into optimal treatment timing in both metastatic and adjuvant settings.

Main Methods:

• Review of randomized trials comparing single-agent therapy, sequential combinations, and concurrent administration of hormone therapy and chemotherapy.
• Analysis of response rates, time to progression, and overall survival data.
• Identification of gaps in comparative studies, particularly regarding concurrent versus sequential treatments.

Main Results:

• Most studies indicate a benefit in response rate or time to progression when chemotherapy is added to hormone therapy or vice versa.
• Statistically significant improvements in response rate or duration are infrequent.
• No studies have reported an improvement in overall survival with combined or sequential therapies.

Conclusions:

• Current evidence does not definitively support concurrent hormone therapy and chemotherapy over sequential approaches for improved survival in metastatic breast cancer.
• Optimal sequencing and concurrent administration strategies require further investigation, especially in the adjuvant setting and specific patient populations.
• The timing of treatment is crucial and warrants further exploration in clinical trials.